ResMed welcomes the European Commission's targeted revision of Regulation (EU) 2017/745 (MDR) and strongly supports its objectives of strengthening the regulatory framework while improving efficiency, predictability and timely patient access to safe and innovative medical technologies. Overall, ResMed considers the proposal to be a positive step towards a more proportionate and future-ready regulatory system.
RES
Resmed
Company · AUS · EU Transparency Register 209143033529-94
4
positions filed
in the 326 files tracked
4
legislative files
of 326 tracked
4
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #218 by legislative files engaged — a count of participation, not a measure of influence.
0.5
declared lobbying FTE
self-declared
€25K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2018
in the register since
Declares membership of
- MedTech Europe: https://www.medtecheurope.org/
- DIGITALEUROPE: https://www.digitaleurope.org/
- European Business Summit https://ebsummits.eu/
- EGN https://be.egn.com/
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- ResMed (RMD)
- Head office
- San Diego, United states
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Resmed in PolicySpeak: request access →
Work at Resmed? so we know who speaks for it.
Their record over time
Resmed filed 4 positions between 26 Jan 2026 and 3 Aug 2026, across 4 of the 326 legislative files tracked here, attaching a full position paper 4 times.
What they argued
Resmed welcomes the opportunity to contribute to the consultation on the revision of EU rules on public procurement. As the EU updates its procurement systems, the new framework should focus more strongly on outcomes, care efficiency, and overall valuenot only cost. This is especially important in healthcare, where quality and innovation directly benefit patients and system performance.
Executive Summary Cardiovascular disease (CVD) causes 1.7 million deaths and costs 282 billion annually in Europe. Obstructive sleep apnoea (OSA) represents one of the most underrecognized yet modifiable risk factors in CVD management across the European Union.
In response to the Digital Fitness Check Call for Evidence, Resmed urges policymakers to ensure a coherent, harmonised and innovation-friendly European Union digital framework for medical technologies. Over the past decade, the EU has developed an extensive body of legislation on data protection, health data, cybersecurity, artificial intelligence and product safety.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- MedTech Europe · 4 files in common
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
- HOPE (EUROPEAN HOSPITAL AND HEALTHCARE FEDERATION) · 3 files in common
- Siemens Healthineers · 3 files in common
- Royal Philips · 3 files in common
Showing 5 of 54.
Is this your organization?
Everything on this page comes from Resmed’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.